Psychedelic substances such as LSD, psilocybin and MDMA have increasingly become the focus of science and clinical practice in recent years. The substances are used as part of so-called psychedelic-assisted therapies (PAT), in which psychotherapeutic treatment is combined with the temporary administration of these substances. After research and clinical use largely came to a standstill in the 1970s, modern, controlled studies are now available that provide promising but not yet conclusive data on efficacy and safety.
Autoren
- PD Dr. med. Felix Müller
- Dr. phil. Helena D. Aicher
- Prof. Dr. med. Undine E. Lang
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Psychedelic-assisted therapy
Current status of PAT
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Psoriasis and Obesity: Effects of Incretin-Based Therapies
Clinical trials shed light on the potential of semaglutide, liraglutide, and tirzepatide
- Eosinophils in the Blood in COPD
How many measurements are needed to be sure?
- From symptom to diagnosis
Abdominal Pain – Von Meyenburg Complexes of the Liver
- Multiple sclerosis
Physical and psychosocial fatigue have the greatest impact on HRQoL
- Congenital Vascular Malformations
Personalized Treatment Before a Planned Pregnancy
- Hyperhidrosis: Keep a Cool Head